Metformin and vildagliptin combination: A new approach of endothelial nitric oxide synthase activity regulation and metabolism in diabetes mellitus type 2

This review analyzes the research results of additional effects and mechanisms of action of sugar-reducing drugs. Hence it has been suggested that asymmetric dimethylarginine may be a target molecule for metformin, vildagliptin, and combinations thereof.